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COMMENTARY
Glycosylated haemoglobin (A1c) best values 
for type 2 diabetes in the battlefield much ado 
about nothing? (apparently)
Davide Maggi1,2, Fabrizio Montecucco3,4, Gianfranco Adami1,2 and Renzo Cordera1,2*
Abstract 
Despite intensive research, therapy of diabetes mellitus type 2 (T2DM) is far from be effective. The most important 
unresolved issue is to establish a safe glycosylated hemoglobin C (A1c) value well balanced between benefit and side 
effects. As a result different guidelines suggest different A1c targets generating confusion for patients and clinicians. 
Here we report two observations which might support a relaxed A1c as suggested by American college of physician 
(ACP).
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Background
“The prevalence of type 2 diabetes mellitus (T2DM) is 
rapidly increasing and represents a serious burden for 
patients and health care systems. Both impaired beta-cell 
function and insulin resistance contribute to hyperglyce-
mia, the diagnostic hallmark of diabetes. Correction of 
hyperglycemia is therefore considered a priority of diabe-
tes therapy and it has been pursued with drugs increasing 
insulin secretion and/or decreasing insulin resistance and 
obesity, a state of insulin resistance not only simply asso-
ciated with diabetes but, more important, being a key 
factors linking T2DM and cardiovascular diseases (CV), 
the common clinical outcome of diabetes”. This link is so 
strong that even a modest weight loss is often successful 
to improve hyperglycemia [1]. Also diabetes remission is 
observed short time after bariatric surgery before clinical 
meaningful weight loss [2].
In the last 20  years several clinical trials, designed to 
correct of hyperglycemia, have been consistently suc-
cessful to prevent and to decrease microvascular compli-
cations of diabetes, while macrovascular complications 
have been only marginally affected by glucose control.
For many years, insulin, sulfonylureas and biguanides 
were the only available antidiabetic drugs and their 
failure to prevent CV diseases has been attributed to 
the difficulty to lower enough blood glucose concentra-
tion due to increased risk of hypoglycemia and increased 
body weight.
Recently, new classes of antidiabetic drugs with a better 
clinical profile have become available: it should be rec-
ognized however that these new drugs are less prone to 
cause hypoglycemia but pay different clinical tolls, most 
of them probably unknown. Unfortunately their anti-
hyperglycemic potency is superimposable to that of older 
drugs and none of them is a disease modifier in term of 
atherosclerotic complications.
Addressing therapy to glucose control has two main 
aims: to avoid acute glycemic crisis and to reduce vas-
cular complications. Since vascular complications take 
years to develop it is not surprising the need long lasting 
therapy to demonstrate a benefit from a particular strat-
egy or medication.
This means a significant lag-time between glucose con-
trol and reduction of vascular complications. As a con-
sequence a patient could suffer from early side effects of 
therapy without a guarantee of clinical advantages in the 
long term follow up.
The best glucose control, as A1c to be pursued in a sin-
gle patient with a balance between early side effects and 
future benefits is a highly debated issue. Guidelines are 
not concordant on A1c value, leaving clinician without 
clears indications and generating concern in patients 
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and doctors. Treatment of hyperglycemia is not free 
of complications, and might, by itself, lead to increased 
mortality, poor quality of life, increased cost. A tailored 
A1c value for each patient should be the best strategy 
allowing to establish a strict control. Thus “the lower the 
blood glucose, the lower the risk of microvascular com-
plications” may be unrealistic. As a consequence in the 
absence of clear guidelines it is not surprising that estab-
lishing an A1c target depends on the physicians attitude 
more than on guidelines themselves and on the identifi-
cation of those frail patients that never would get advan-
tage from very strict glycemic controls.
It is easy to predict that in the next future choosing a 
more or less strict glucose control will not be based on 
evidence based medicine.
In 2018, the American college of physicians (ACP) pub-
lished revised guidelines for T2DM suggesting to target a 
7–8% A1c in most subjects with diabetes. This statement 
was followed by big criticism and was refused by diabe-
tes and endocrine organizations [3]. It is bitter to admit 
that the same body of evidence gave rise to quite differ-
ent clinical advises. One year later, differences between 
guidelines still persist, with the result of more confusion 
for both patients and physicians.
One should ask: is there a real clinical difference 
between HbA1c target values varying of 0.5%? [3]. At 
first glance a 0.5% lower A1c sound trivial, but in clini-
cal practice means more drugs, more side effects, high 
cost and increased life burden. The suggestion by ACP, 
but not ADA, to weaken intensive antidiabetic therapy 
if HbA1c is 6.5% or lower is suggestive of a different 
view on the importance of glucose lowering. This debate 
unfortunately did not determine any change in previous 
targets, leaving clinicians without clear indications on 
best HbA1c target.
We propose two further observations that might favor 
the ACP suggestions for a higher still safe HbA1c target: 
a different interpretation on early data of an association 
between glucose control and microvascular complica-
tions and the observation in monogenic types of diabetes 
of the different incidence of microvascular complica-
tions, correlated with HbA1c values consistent with the 
safety of values around 7–8%.
Revisiting Pirart observation, it should be noticed 
that microvascular diabetic complications were more 
frequent in patients with higher glycosuria [4]. At that 
time, these data were considered as a proof that for 
blood glucose “the lower is better” for patients. Indeed, 
these results might support another conclusion: gly-
cosuria threshold might represent a threshold glucose 
plasma concentration above which micro- and macro-
vascular complications can be accelerated in the pres-
ence of other risk factors. The UK Prospective Diabetes 
Studies (UKPDS), designed to demonstrate that insu-
lin was better than diet advice for preventing diabetic 
complications, was unable to help to establish a safe 
glucose goal. Even if correlations between blood glu-
cose and microvascular complications are linear, some 
acceleration of progression of microvascular complica-
tions was shown for HbA1c values higher than 8–8.5% 
[5]; Nevertheless a general consensus on a HbA1c lower 
than 7% as a treatment goal, even if not experimentally 
proven has become generally recommended [3].
The subtype of monogenic diabetes offer some clues 
to further clarify the role of blood glucose on devel-
opment of microvascular complications. patients with 
MODY 2 (maturity onset diabetes of the young) have 
a HbA1c between 7–8% lifelong but do not develop 
significant diabetic complications. On the contrary, 
patients with other types of MODY, such as MODY 3, 
have HbA1c higher than 8.5–9.0% lifelong and develop 
diabetic complications [6].
Medications for blood glucose control in T2DM are 
associated with risk of significant complications, but 
with limited experimental evidence of real benefit: HR 
for death is marginally decreased by lowering HbA1c 
from 8 to 7% as well as progression of development of 
microvascular damage [7].
Conclusion
In our opinion a “safe” HbA1c is that suggested by ACP 
(7–8%) should be recommended and if new treatments 
will bring new evidences, they will be more than wel-
comed. In the mean time a less glucocentric diabetes 
therapy strategy will allow to implement a more com-
prehensive multifactorial therapy”.
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